^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Renal Cell Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Excerpt:
    The benefits of pembrolizumab plus axitinib with respect to overall survival and progression-free survival were observed in all subgroups examined, including all IMDC risk and PD-L1 expression categories.
    DOI:
    10.1056/NEJMoa1816714
    Trial ID:
    KEYNOTE 426